UPDATE: Ascendiant Capital Markets Downgrades Repros Therapeutics to Buy, Reiterates $25 PT Following Announcement of FDA Concerns

In a report published Thursday, Ascendiant Capital Markets analyst Keay Nakae downgraded the rating on Repros Therapeutics RPRX from Strong Buy to Buy, but reiterated the $25.00 price target. In the report, Ascendiant Capital Markets noted, “Yesterday, the company announced that the FDA communicated to them that it has some concerns about the adequacy of including patients enrolled at one clinical site in Miami in the ZA-301 Phase III clinical study that evaluated the safety and efficacy of Androxal for the treatment of low testosterone. As a result, the company has been instructed by the FDA to request a meeting to discuss the issue. Repros expects that this meeting will likely be scheduled some time in December.” Repros Therapeutics closed on Wednesday at $23.69.